Price$24.74-13.35 (-35.05%)
2026-01-142026-04-20
Latest news
25 items- SECSEC Form DEF 14A filed by Synaptogenix Inc.DEF 14A - TAO Synergies Inc. (0001571934) (Filer)
- INSIDERDirector Singer William S. was granted 15,410 shares and covered exercise/tax liability with 6,164 shares, increasing direct ownership by 700% to 10,566 units (SEC Form 4)4 - TAO Synergies Inc. (0001571934) (Issuer)
- INSIDERChief Financial Officer Weinstein Robert was granted 15,410 shares and covered exercise/tax liability with 6,164 shares, increasing direct ownership by 696% to 10,574 units (SEC Form 4)4 - TAO Synergies Inc. (0001571934) (Issuer)
- INSIDERExecutive Chairman Silverman Joshua was granted 41,919 shares and covered exercise/tax liability with 16,768 shares, increasing direct ownership by 1,644% to 26,681 units (SEC Form 4)4 - TAO Synergies Inc. (0001571934) (Issuer)
- INSIDERDirector Schechter Jonathan was granted 21,575 shares and covered exercise/tax liability with 8,630 shares, increasing direct ownership by 1,188% to 14,035 units (SEC Form 4)4 - TAO Synergies Inc. (0001571934) (Issuer)
- INSIDERDirector Bernstein Bruce covered exercise/tax liability with 9,863 shares and was granted 24,657 shares, increasing direct ownership by 1,341% to 15,897 units (SEC Form 4)4 - TAO Synergies Inc. (0001571934) (Issuer)
- INSIDERChief Medical Officer Tuchman Alan J was granted 4,315 shares and covered exercise/tax liability with 1,726 shares, increasing direct ownership by 196% to 3,909 units (SEC Form 4)4 - TAO Synergies Inc. (0001571934) (Issuer)
- PRTAO Synergies (Formerly Synaptogenix) Begins Trading Under New Nasdaq Stock Symbol "TAOX" Effective at Market Open TodayNew name and stock symbol highlight strategic commitment to TAO, the leading AI cryptocurrency NEW YORK, July 1, 2025 /PRNewswire/ -- TAO Synergies Inc. (NASDAQ:TAOX) (the "Company"), formerly Synaptogenix, Inc. (NASDAQ:SNPX), announces that its common stock, listed on the Nasdaq Capital Market, begins trading under the new ticker symbol, "TAOX," effective at the market open today, July 1, 2025. The new name and trading symbol coincides with the Company's previously announced digital asset treasury strategy focused exclusively on acquiring and staking TAO cryptocurrency. Executive Chairman Joshua Silverman commented, "With our team's deep knowledge of the TAO ecosystem and relationships in
- SECSEC Form PRE 14A filed by Synaptogenix Inc.PRE 14A - TAO Synergies Inc. (0001571934) (Filer)
- SECSynaptogenix Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - TAO Synergies Inc. (0001571934) (Filer)
- PRSynaptogenix Announces Name Change to TAO Synergies and New Ticker Symbol "TAOX" for Alignment with AI-Focused Crypto Treasury StrategyNew trading symbol "TAOX" effective Tuesday, July 1, 2025, New name represents Company's strategic focus on the synergies between cryptocurrency and AI NEW YORK, June 26, 2025 /PRNewswire/ -- TAO Synergies Inc. (the "Company"), formerly Synaptogenix, Inc. (NASDAQ:SNPX), today announced that it will begin trading on Nasdaq under the new ticker symbol "TAOX" on Tuesday, July 1, 2025, in accordance with its rebranding to the new name TAO Synergies Inc., effective today. The Company's new corporate identity aligns with its significant strategic focus on the leading AI token TAO as the cornerstone of its digital asset treasury strategy. TAO is the leading AI token by market capitalization and
- SECSynaptogenix Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Synaptogenix, Inc. (0001571934) (Filer)
- PRSynaptogenix Announces Initial TAO Acquisition under Crypto Treasury Strategy, Appoints BitGo as Custodian, and Commences Yield Generation Through StakingStrategic capital deployment into TAO advances Synaptogenix's blockchain treasury model, leveraging BitGo's custody, trading and staking capabilities to generate token-based yield NEW YORK, June 24, 2025 /PRNewswire/ -- Synaptogenix (NASDAQ:SNPX) today announced its initial purchase of TAO as part of the Company's recently announced cryptocurrency treasury strategy focused exclusively on artificial intelligence (Al) and machine learning. BitGo, the leading infrastructure provider of digital asset solutions, has been selected to provide qualified custody, staking and trading services for Synaptogenix's TAO holdings. BitGo brings unmatched expertise and a proven track record to help Synaptogen
- SECSEC Form D filed by Synaptogenix Inc.D - Synaptogenix, Inc. (0001571934) (Filer)
- SECSynaptogenix Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Synaptogenix, Inc. (0001571934) (Filer)
- PRSynaptogenix Appoints Crypto Expert to Lead Digital Asset Treasury Strategy Focused Exclusively on Top-Valued AI TokenSingular focus on Bittensor (TAO), the leading AI token byadoption and market capitalization James Altucher to lead TAO token strategy initiatives Planned initial acquisition of $10 million in TAO equates to over two times the Company's current market capitalization; total acquisition target of $100 million NEW YORK, June 9, 2025 /PRNewswire/ -- Synaptogenix, Inc. (NASDAQ:SNPX) ("Synaptogenix" or the "Company") today announced its launch of a differentiated cryptocurrency treasury strategy focused exclusively on the artificial intelligence (AI) crypto token "TAO," which is currently the top AI token by market capitalization and adoption. Well-known cryptocurrency and AI expert James Altuch
- SECSEC Form 10-Q filed by Synaptogenix Inc.10-Q - Synaptogenix, Inc. (0001571934) (Filer)
- INSIDERSEC Form 4 filed by Director Singer William S.4 - Synaptogenix, Inc. (0001571934) (Issuer)
- INSIDERSEC Form 4 filed by Director Schechter Jonathan4 - Synaptogenix, Inc. (0001571934) (Issuer)
- INSIDERSEC Form 4 filed by Director Bernstein Bruce4 - Synaptogenix, Inc. (0001571934) (Issuer)
- SECSEC Form 10-K filed by Synaptogenix Inc.10-K - Synaptogenix, Inc. (0001571934) (Filer)
- SECSynaptogenix Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Synaptogenix, Inc. (0001571934) (Filer)
- PRSynaptogenix Board of Directors Forms Special Committee to Explore Value Creation Opportunities Utilizing Balance Sheet Strength$19.6 million in cash and cash equivalents as of September 30, 2024 Dramatically reduced cash burn rate expected NEW YORK, Dec. 20, 2024 /PRNewswire/ -- Synaptogenix, Inc. (NASDAQ:SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced that its Board of Directors has formed an independent Special Committee to explore strategic opportunities to create and enhance value for investors. Funding for such opportunities is supported by the Company's robust financial position including $19.6 million in cash as of September 30, 2024, with approximately 1.3 million common shares outstanding. "Synaptogenix
- SECSynaptogenix Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - Synaptogenix, Inc. (0001571934) (Filer)
- SECSEC Form DEFA14A filed by Synaptogenix Inc.DEFA14A - Synaptogenix, Inc. (0001571934) (Filer)
SNPX FAQ
5 questionsWhat does Synaptogenix Inc. do?
Synaptogenix, Inc. operates as a biopharmaceutical company. It focuses on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and niemann-pick type C disease. It has licensing agreements with Stanford University; Icahn School of Medicine; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and...Where does SNPX stock trade?
Synaptogenix Inc. (SNPX) is listed on NASDAQ.What sector and industry is SNPX in?
Synaptogenix Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What companies are similar to SNPX?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare SNPX side-by-side with any of them on Quantisnow.How can I track SNPX on Quantisnow?
Quantisnow aggregates Synaptogenix Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SNPX to receive live email and push alerts on every new disclosure.